<DOC>
	<DOCNO>NCT01158079</DOCNO>
	<brief_summary>This study provide mechanism continue administration ALN-VSP02 therapy patient cancer complete participation another ALN-VSP02 clinical study . The primary objective study collect long term safety data .</brief_summary>
	<brief_title>Multi-center , Open Label , Extension Study ALN-VSP02 Cancer Patients Who Have Responded ALN-VSP02 Treatment</brief_title>
	<detailed_description>Study ALN-VSP02 extension study previously conduct ALN-VSP02 study . The study conduct allow continue ALN-VSP02 therapy patient complete participation ALN-VSP02 clinical study , achieve clinical benefit ALN-VSP02 ( i.e. , disease response stable disease well ) , , Investigator 's opinion , may benefit continuation ALN-VSP02 therapy .</detailed_description>
	<criteria>1 . Patient complete previous ALNVSP02 study , deem stable disease well . 2 . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status score 01 . 3 . Patient adequate hematologic , liver , renal function . 1 . Patient receive fulldose ( therapeutic ) anticoagulation therapy and/or aspirin &gt; 325 mg/day platelet inhibitory agent . 2 . Patient clinically significant cardiovascular disease uncontrolled serious cardiac arrhythmia . 3 . Patient clinically significant cerebrovascular disease . 4 . Patient seizure disorder control medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Liver</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Advanced Solid Tumors Liver Involvement</keyword>
</DOC>